{
  "docId": "019de076-91e2-76fd-b3d2-f30dde172711",
  "docSlug": "0239a71f9c69421092604a0a694fdb09",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 26 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 26,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_messages",
  "function": "quantify_opportunity",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a table comparing hospitalization rates for RSV, hMPV, and Influenza across age groups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-91e2-76fd-b3d2-f30dde172711/14",
  "deckHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711",
  "deckJsonHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711.json",
  "deckAnchorHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.38,
        "y": 0.38
      },
      "kind": "image",
      "text": "IVX-121 + IVX-241 = IVX-A12",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94db5ed0-21cb-4cae-ae9b-4e9da38fb3f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.6,
        "y": 0.35
      },
      "kind": "list",
      "text": "IVX-A12 potential for greater immunogenicity and durability vs approved RSV vaccines; Potential to be the first RSV combination vaccine and the first hMPV vaccine; Adult RSV market estimated >$10-15bn; FDA Fast Track designation; Phase III ready",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8ab2743-5bee-487c-b762-75bcc4de8e18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.28,
        "x": 0.06,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Building novel vaccines and antibodies portfolio",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6db212f9-0f59-40b0-94cc-a179772ee758",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Icosavax acquisition remains subject to customary closing conditions... 2. Airfinity... 3. Adjusted, weighted rates of hospitalization per 10,000 adults >=50 years of age",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cb16374-cbb5-4dc8-8c76-138790c54280",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.6,
        "y": 0.65
      },
      "kind": "table",
      "text": "RSV and hMPV hospitalization rates similar to Influenza: 50-64 years (8.2, 1.8, 11.5), >=65 years (25.4, 22.1, 12.3), Overall (15.0, 9.8, 11.8)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76f5714b-69d6-4b83-90bc-8383a683d6a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "title",
      "text": "Accelerating strategy focused on serious respiratory illness, building on existing expertise",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3897fb79-4eef-4ccc-8cf7-021c3605333c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "V&I— substantial growth potential addressing high unmet needs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7313cdf-9075-47f0-8382-dbbeb111393b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "aadac6c5-85ff-4c00-8a67-6ccfa3236c41",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Rising Success",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "The deck showcases AstraZeneca's successes in various disease areas, including oncology and rare disease.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}